Swiss drug-making giant Roche has apparently stepped up its efforts to acquire American gene therapy company Spark for $4.3 billion, according to widespread reports. More importantly, Roche Chief Executive Officer Severin Schwan went on record on Monday and stated that the advancements made by Spark in the field of gene…
